LUPUS NEPHRITIS (LN)
Clinical trials for LUPUS NEPHRITIS (LN) explained in plain language.
Never miss a new study
Get alerted when new LUPUS NEPHRITIS (LN) trials appear
Sign up with your email to follow new studies for LUPUS NEPHRITIS (LN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy aims to reset immune system in Tough-to-Treat lupus
Disease control Not yet recruitingThis early-stage study is testing a personalized cell therapy called C-CAR168 for people with severe lupus kidney disease that hasn't improved with standard treatments. Doctors will collect a patient's own immune cells, modify them to target specific markers on harmful immune cel…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for lupus patients: repurposed drug trial aims to shield kidneys
Disease control Not yet recruitingThis small pilot study is testing if adding the drug dapagliflozin to standard treatment helps control kidney damage in people with active lupus nephritis. The trial will involve 33 adults who have recently been diagnosed with or had a flare-up of this serious kidney complication…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Cancer-Fighting cell therapy tested for devastating lupus kidney damage
Disease control Not yet recruitingThis early-stage study is testing a new personalized cell therapy called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and potentially reset the faulty immu…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Radical immune 'Reset' tested as potential lifeline for Tough-to-Treat lupus
Disease control Not yet recruitingThis early-stage study is testing a new type of cell therapy called ICG318 for people with severe, hard-to-treat systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remo…
Matched conditions: LUPUS NEPHRITIS (LN)
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC